Second-Line Immunosuppression for Steroid-Resistant IgA Nephropathy
For this patient with steroid-resistant IgA nephropathy after 5 months of methylprednisolone and persistent proteinuria >1 g/24h, add cyclophosphamide combined with continued corticosteroids as second-line therapy.
Rationale for Cyclophosphamide
The most recent KDIGO 2025 guideline for IgAN 1 does not recommend routine use of cyclophosphamide, azathioprine, or calcineurin inhibitors in typical IgAN. However, your patient's clinical presentation—steroid resistance with persistent proteinuria, hypertension, and edema after 5 months of therapy—suggests more aggressive disease that may benefit from cytotoxic therapy.
Evidence Supporting Cyclophosphamide in Resistant IgAN
The strongest evidence comes from patients with active histological lesions:
In crescentic/proliferative IgAN with clinical progression, pulse methylprednisolone (15 mg/kg for 3 days) followed by monthly IV cyclophosphamide (0.5 g/m² for 6 months) reduced mean serum creatinine from 2.65 to 1.51 mg/dl and proteinuria from 4.04 to 1.35 g/24h 2
A 2000 study demonstrated that prednisone combined with cyclophosphamide (1.5 mg/kg for 2 months) in IgAN patients with florid crescents achieved 91.6% 5-year renal survival versus 37.5% in untreated controls 3
Recent 2026 data showed that prednisone plus cyclophosphamide in IgAN with partial crescents reduced proteinuria from 1,534 mg/day to 289.5 mg/day at 24 months, with 60% achieving effective remission 4
Recommended Treatment Protocol
Induction regimen:
- Methylprednisolone: 1 g IV daily for 3 consecutive days (pulse therapy)
- Cyclophosphamide: 0.5 g/m² IV monthly for 6 months
- Oral prednisone: Continue at reduced dose (0.4-0.5 mg/kg/day), then taper over subsequent months
Duration: Minimum 6 months of cyclophosphamide therapy to assess response 2, 3
Alternative Second-Line Options
Mycophenolate Mofetil (MMF)
If cyclophosphamide is contraindicated or not tolerated:
- MMF 2 g/day for 6 months combined with 3 pulses of methylprednisolone (15 mg/kg) followed by short-course oral prednisone achieved similar outcomes to conventional steroid protocols while sparing 6 g cumulative steroid dose 5
- This regimen is particularly appropriate if the patient has risk factors for cyclophosphamide toxicity (young age, fertility concerns)
Azathioprine
A less aggressive option:
- Azathioprine 1.5-2 mg/kg/day combined with steroids showed efficacy in reducing proteinuria from 2.4 to 0.7 g/24h 6
- Consider if patient has partial response to steroids but requires steroid-sparing maintenance 6
Critical Caveats
Do NOT use these regimens if:
- eGFR <30 ml/min/1.73 m² (increased toxicity risk) 7
- Active infection present
- Uncontrolled diabetes or significant obesity
- No evidence of active inflammatory lesions on biopsy (if available)
The STOP-IgAN trial 8 showed that cyclophosphamide followed by azathioprine in patients with eGFR 30-59 ml/min/1.73 m² did NOT prevent GFR loss and was associated with substantial adverse events. This underscores that cyclophosphamide should be reserved for patients with documented active inflammatory disease, not chronic sclerotic changes.
Monitoring Requirements
- Infection prophylaxis: Pneumocystis jirovecii prophylaxis (trimethoprim-sulfamethoxazole) mandatory during cyclophosphamide therapy 1
- Monthly monitoring: Complete blood count, liver function, renal function
- Assess response at 6 months: Proteinuria reduction ≥50% and stable/improved renal function indicates response 2
If This Fails
If no response after 6 months of cyclophosphamide:
- Consider rituximab as salvage therapy (375 mg/m² or 1 g doses), though evidence in IgAN is limited to case reports 9
- Re-evaluate for secondary causes of proteinuria
- Consider repeat biopsy to assess for progression to chronic sclerotic changes that would not benefit from further immunosuppression
The key distinction: Cyclophosphamide works in IgAN with active inflammatory lesions (crescents, endocapillary proliferation), not in chronic disease. Without biopsy confirmation of active lesions, the risk-benefit ratio shifts unfavorably.